A Randomized, Double-blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets in Male Subjects with Premature Ejaculation.
- Conditions
- Premature EjaculationMedDRA version: 9.1Level: LLTClassification code 10036596Term: Premature ejaculation
- Registration Number
- EUCTR2009-011411-21-BG
- Lead Sponsor
- Biovail Laboratories International SRL, c/o Biovail Technologies Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Male
- Target Recruitment
- 1050
Subjects are eligible for study participation if all of the following criteria are met:
1. Male subject and female partner to provide written informed consent prior to the performance of any study-specific procedures;
2. Candidates will be male subjects aged 18-65 years inclusive, with lifelong premature ejaculation (lifelong” is defined as starting at the time the subject became sexually active) with an IELT of =120 seconds as documented at Visit 2.
3. History of premature or rapid ejaculation, determined by following criteria in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM IV TR):
a) Persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after vaginal insertion and before the person wishes it, taking into account factors that affect duration of the excitement phase such as age, novelty of the sexual partner or situation and recent frequency of sexual activity
b) The disturbance causes marked distress or interpersonal difficulty
c) The premature ejaculation is not due exclusively to the direct effects of a substance (ab)use
4. In a stable, monogamous, heterosexual relationship (> 6 months).
5. Willing and able to take study medication as directed at least 2 hours prior to sexual intercourse according to protocol;
6. Subject willing and able to complete the therapeutic trial, all sexual behavior logs, IELT assessments, questionnaires and interviews:
7. Female sexual partner willing and able to complete the therapeutic trial, all sexual behavior logs, IELT assessments, questionnaires and interviews;
8. Able to understand the study procedures, complete the assessments, and communicate with study personnel;
9. Subject and partner willing and able to engage in vaginal intercourse at least three times between visits to yield at least three events of vaginal intercourse ;
10. Subject and partner willing to use a reliable contraceptive method during the trial period if the partner is not menopausal;
11. Partner willing to take pregnancy tests at Visits 1 and 2
12. Subject willing to list and document prescription and non-prescription drug use during the study;
13. Have a negative urine drug screen at Visits 1 and 2;
14. Be in good general health as determined by medical history and physical examination and expected by the Investigator to complete the study as designed
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Subjects are not eligible for study participation if any of the following criteria are met:
1. Premature ejaculation attributable to situational or relationship issues;
2. Evidence or a history of other significant psychiatric disorder as defined as requiring therapy or medication;
3. Subjects who in the Investigator’s opinion are at significant risk of suicide.
4.Physical illnesses: History of seizures, Prostatitis (current), Urethritis or other urinary tract infections (current), Prior genital surgery (other than vasectomy or circumcision), Uncontrolled Diabetes mellitus, Respiratory Depression, Thyroid disease, Chronic moderate to severe neurological disease, Significant heart disease treated with cardiac drugs, Chronic liver disease and kidney disease, History of cardiovascular disease (myocardial infarction, congestive heart failure, angina, coronary artery disease or stroke), Known to be a carrier of the hepatitis B surface antigen, hepatitis C virus antibody, and/or immunodeficiency virus-1 and/ or 2 antibodies, Other disorder that may cause sexual dysfunction
5. Other sexual dysfunction: Erectile dysfunction. As defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV TR), the diagnostic criteria for male erectile disorder (302,72) erectile dysfunction includes: A. Persistent or recurrent inability to attain, or to maintain until completion of the sexual activity, an adequate erection, B. The disturbance causes marked distress or interpersonal difficulty, Primary reduced sexual desire unrelated to premature ejaculation
6. Sexual intercourse usually less than once per week;
7. Partner sexual dysfunction (for example dyspareunia or other conditions considered relevant);
8. Current use of dapoxetine;
9. Current use of any tramadol;
10. Sensitivity to phenylketone;
11. Any history of abuse of prescription opioids and/or illicit/illegal addictive drugs;
12. Has a known hypersensitivity to heparin or history of heparin induced thrombocytopenia;
13. Use of medication, within the preceding 30 days, with potential to cause sexual dysfunction: Antidepressants – all types, Antipsychotic medication, Antihypertensive medication, unless on a stable dose > 6 months, Hormonal drugs, Chemotherapy and others: cimetidine, clofibrate,quinidine
14. Recent psychotropic drug use (within the past 30 days);
15. A history of alcohol abuse or dependence within the past 6 months as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV TR);
16. Initiation of psychosexual counseling during the screening, baseline or treatment periods;
17. Partner positive pregnancy test at Visit 1 or 2;
18. History of clinically significant intolerance or a known hypersensitivity to tramadol, such that treatment with it is contraindicated;
19. The Investigator anticipates that the subject will be unable to comply with the protocol;
20. Received any investigational drug within 30 days prior to Visit 1 or is scheduled to receive an investigational drug during the course of this study;
21. Has preplanned surgery or procedures that would interfere with the course of the study.
22. A family member (other than the female partner), a staff member, or relative of a staff member.
23. Significant laboratory abnormality as determined by the Investigator at Visit 1;
24. Significant ECG abnormality at Visit 1 as determined by the Investigator;
25. Any other illnesses, conditions or practices that in the Investigator’
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To evaluate the efficacy of 62 mg and 89 mg of Tramadol HCl ODT (hereafter referred to as tramadol) in improving both Intravaginal Ejaculation Latency Time (IELT) and the Premature Ejaculation Profile (PEP).;Secondary Objective: The secondary objective is to evaluate the safety and tolerability of the same two doses of tramadol when given to delay ejaculation.;Primary end point(s): The following information will be collected as co - primary endpoints to evaluate the efficacy of Tramadol HCl ODT:<br><br>•IELT.<br>•PEP – a composite endpoint for questionnaires for males and questionnaires for females<br><br>The secondary efficacy measures will consist of the following assessments:<br><br>•Sexual Quality of Life for Men Questionnaire (SQOL-M)<br>•Subject Global Satisfaction Assessment<br>
- Secondary Outcome Measures
Name Time Method